Neuropeptide Y expression distinguishes malignant from benign pheochromocytoma.
No reliable gross or microscopic features distinguish benign from malignant pheochromocytomas. The diagnosis of malignant pheochromocytoma is based solely on the presence of regional or distant metastases. This study evaluated the expression of neuropeptide Y messenger RNA (mRNA) in nine benign and 11 malignant pheochromocytomas and has found that neuropeptide Y mRNA was expressed in all nine benign tumors but in only four of 11 malignant tumors (P = .0084). These data suggest that the determination of neuropeptide Y expression in the evaluation of patients with pheochromocytoma may have prognostic significance.
Helman
L J
LJ
Pediatric Branch, National Cancer Institute, Bethesda, MD 20812.
Cohen
P S
PS
Averbuch
S D
SD
Cooper
M J
MJ
Keiser
H R
HR
Israel
M A
MA
D000310:Adrenal Gland Neoplasms / Q000175:diagnosis* / Q000235:genetics / Q000473:pathology; D015152:Blotting, Northern; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D007150:Immunohistochemistry; D009478:Neuropeptide Y / Q000235:genetics* / Q000378:metabolism; D009693:Nucleic Acid Hybridization; D010673:Pheochromocytoma / Q000175:diagnosis* / Q000235:genetics / Q000473:pathology; D012333:RNA, Messenger / Q000235:genetics
D009478:Neuropeptide Y; D012333:RNA, Messenger